Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Goals
Fat LossMuscle BuildingInjury HealingAnti-AgingCognitive EnhancementSleep OptimizationImmune SupportGut HealingSkin RejuvenationSexual Health
Peptides
Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PNC-27
Cancer Research
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 32
Back to Home

Peptide Comparison

LentinanvsThymosin Alpha-1

Mushroom-derived β-glucan polysaccharide with potent immunomodulatory and antitumor properties approved for cancer therapy in Japan

Your immune system's master trainer—a naturally occurring thymus peptide that wakes up tired immune cells, helps your body fight infections, and keeps your defenses sharp as you age.

ImmuneImmune

At a Glance

Quick
comparison

Dose Range

Lentinan

2–10 mg

Thymosin Alpha-1

1.6–3.2 mg

Frequency

Lentinan

Once weekly

Thymosin Alpha-1

Twice weekly

Administration

Lentinan

Intravenous infusion

Thymosin Alpha-1

Subcutaneous injection

Cycle Length

Lentinan

8-12 weeks

Thymosin Alpha-1

8-12 weeks

Onset Speed

Lentinan

Moderate (1-2 weeks)

Thymosin Alpha-1

Moderate (1-2 weeks)

Evidence Level

Lentinan

Moderate human trials (Phase 1-2)

Thymosin Alpha-1

Moderate human trials (Phase 1-2)

Efficacy

Benefit
ratings

Lentinan
Thymosin Alpha-1

Immune

Lentinan95%
Thymosin Alpha-10%

Healing & Recovery

Lentinan70%
Thymosin Alpha-10%

Anti-Aging

Lentinan40%
Thymosin Alpha-10%

Immune Activation

Lentinan0%
Thymosin Alpha-195%

Infection Fighting

Lentinan0%
Thymosin Alpha-192%

Immune Balance

Lentinan0%
Thymosin Alpha-188%

Technical Data

Compound
specifications

Lentinan

Molecular Formula

(C6H10O5)n (repeating glucose units)

Molecular Weight

~500,000 g/mol (varies by preparation)

Half-Life

Approximately 15-30 minutes (IV administration)

Bioavailability

100% (intravenous administration)

CAS Number

37339-90-5

Thymosin Alpha-1

Molecular Formula

C129H215N33O55

Molecular Weight

3108.32 g/mol

Half-Life

Approximately 2 hours

Bioavailability

High when injected subcutaneously (rapid absorption, peak at ~2 hours)

CAS Number

62304-98-7

Protocols

Dosing
tiers

Lentinan

starting

2 mg IV infusion once or twice weekly

Once or twice weekly

Continued alongside chemotherapy cycles (8-12 weeks or longer)

The standard clinical dose is 2 mg administered by slow intravenous drip infusion (over 30-60 minutes — never as a rapid bolus). Treatment typically continues alongside chemotherapy for multiple cycles. The infusion should be administered slowly to minimize the risk of anaphylactic reactions.

standard

4-10 mg IV infusion weekly

Weekly

As determined by treating oncologist

Higher doses (4-10 mg weekly) have been used in some clinical settings, particularly in HIV studies and for patients with significant immunosuppression. Dose escalation should be gradual and monitored for adverse reactions. Higher doses are associated with increased risk of side effects including granulocytopenia.

advanced

Shiitake mushroom extract 1-5 g daily (standardized to lentinan content)

Daily

Ongoing as dietary supplement

While purified lentinan for IV injection is the clinically studied form, oral shiitake mushroom extracts standardized for β-glucan content are available as dietary supplements. Oral bioavailability of intact lentinan is limited compared to IV administration. Oral extracts may provide general immune support but should not be considered equivalent to IV lentinan for cancer therapy.

Thymosin Alpha-1

starting

1.6 mg

Twice weekly

4 weeks

This is the standard clinical dose used in most research trials. Start here to assess your tolerance and response. The 1.6 mg dose (sometimes listed as 900 mcg/m2) has decades of safety data behind it.

standard

1.6 mg

Twice weekly

8-12 weeks

The most common protocol used in clinical trials for hepatitis and cancer support. Inject on consistent days (like Monday/Thursday) for best results. This duration allows meaningful immune enhancement.

advanced

1.6 mg daily for 7 days, then twice weekly

Daily initially, then twice weekly

12+ weeks

Used in some severe infection and critical care protocols. The daily loading phase rapidly boots immune function, followed by maintenance. Only under medical supervision for serious conditions.

Applications

Best
suited for

Lentinan

Advanced Gastric Cancer

Lentinan's primary and best-studied indication is as an adjuvant to chemotherapy for unresectable and recurrent gastric cancer. A multi-institutional randomized trial demonstrated significantly extended survival (297 vs 199 days median) and dramatically improved one-year survival rates (49.1% vs 0%).

Lung Cancer Adjuvant Therapy

A 12-year review of clinical studies in China demonstrated that lentinan combined with chemotherapy improves outcomes in lung cancer patients, with a meta-analysis confirming increased chemotherapy efficacy and improved quality of life.

Cancer Patients Needing Quality of Life Support

Clinical trials consistently show lentinan improves patient quality of life during cancer treatment, particularly appetite and sleep quality, while reducing the toxic side effects of chemotherapy and enabling treatment continuity.

Immunocompromised Patients

Phase 1/2 clinical trials in HIV-positive patients have explored lentinan's ability to enhance immune function when combined with antiretroviral therapy, though this application remains investigational.

Thymosin Alpha-1

Chronic Hepatitis B or C Support

Thymosin Alpha-1 has its strongest clinical evidence here. Multiple trials show it helps clear viral loads and normalize liver enzymes, especially when combined with antiviral medications. It's approved in over 30 countries specifically for hepatitis treatment.

Cancer Treatment Support

When used alongside chemotherapy, Thymosin Alpha-1 may help maintain immune function that chemo tends to suppress. Research in lung cancer, melanoma, and liver cancer shows improved outcomes when added to standard treatments. It helps your immune system keep fighting even during tough treatments.

Age-Related Immune Decline

As you age, your thymus shrinks and produces less thymosin naturally—a process called immunosenescence. Supplementing with Thymosin Alpha-1 may help compensate, keeping your immune defenses more youthful and responsive. Think of it as replacing what your body makes less of over time.

Severe Infection Recovery

In sepsis and critical infections, Thymosin Alpha-1 has shown promise for reducing mortality by helping restore immune balance. It's particularly interesting because it modulates immunity rather than just boosting it—calming overreaction while enhancing pathogen-fighting ability.

Safety Profile

Side
effects

Lentinan

Common

  • Fever and chills
  • Infusion site discomfort
  • Transient fatigue
  • Nausea

Uncommon

  • Chest tightness or back pain
  • Granulocytopenia

Serious

  • Anaphylaxis
  • Severe allergic reaction / Anaphylaxis

Thymosin Alpha-1

Common

  • Injection site reactions
  • Mild fatigue
  • Flu-like symptoms

Uncommon

  • Mild fever
  • Lymph node awareness

Serious

  • Allergic reaction

Research Status

Safety
& evidence

Lentinan

Evidence Level

Moderate human trials (Phase 1-2)

FDA Status

Research compound

Safety Overview

Lentinan is a beta-1,3-glucan polysaccharide (not a true peptide) extracted from shiitake mushroom with a 40-year safety record in Japanese and Asian oncology practice. Parenteral lentinan shows excellent tolerability as an immune adjuvant with minimal systemic toxicity—hepatotoxicity and nephrotoxicity are essentially absent in clinical use. Fever and localized reactions at injection sites (5-15% of patients) are the documented side effects. The compound works through pattern recognition receptors (Dectin-1, TLR-2) to enhance NK cell and macrophage function without inducing autoimmunity.

Contraindications

  • xKnown hypersensitivity to lentinan or shiitake mushroom components
  • xHistory of anaphylactic reactions to β-glucan polysaccharides
  • xSevere immunosuppression where immune activation is contraindicated
  • xActive autoimmune disease in flare (immune stimulation could worsen)

Thymosin Alpha-1

Evidence Level

Moderate human trials (Phase 1-2)

FDA Status

FDA approved for other use

Safety Overview

Thymosin Alpha-1 has one of the most extensive safety records of any peptide, with decades of clinical use across multiple countries. Studies consistently report minimal side effects—mostly limited to mild injection site reactions. The 2-hour half-life means it doesn't accumulate in your system. It's been used safely in thousands of patients with hepatitis, cancer, and other serious conditions.

Contraindications

  • xOrgan transplant recipients on immunosuppressants
  • xActive autoimmune disease flares
  • xKnown allergy to thymosin peptides
  • xPregnancy or breastfeeding
  • xChildren under 18 without medical supervision

Decision Guide

Which is
right for you?

Choose Lentinan if...

  • Adjunctive cancer therapy (especially gastric cancer)
  • Immune system enhancement during chemotherapy
  • Improving quality of life for cancer patients
  • Supporting immune function in immunocompromised individuals

Choose Thymosin Alpha-1 if...

  • Immune system strengthening
  • Chronic infection support
  • Cancer adjunct therapy
  • Healthy aging immune support